AXA Framlington Biotech Fund GBP Z Acc

Investment Style Details30/11/2019
Morningstar Style Box®
Equity Style
SizeRel to Cat
Average Mkt Cap (Mil)GBP 10134-
Market Capitalisation% of Equity
Giant11.70
Large35.42
Medium28.13
Small18.04
Micro6.71
Valuations and Growth RatesEquity PortfolioRelative to Category
Price/Prospective Earnings14.450.68
Price/Book4.170.90
Price/Sales5.661.00
Price/Cash Flow13.611.07
Dividend-Yield Factor0.591.39
 
Long-Term Projected Earnings Growth9.270.66
Historical Earnings Growth22.400.87
Sales Growth6.630.53
Cash-Flow Growth5.650.80
Book-Value Growth6.670.57
 
Asset Allocation30/11/2019
Asset Allocation
 % Long% Short% Net Assets
Stock94.730.0094.73
Bond0.000.000.00
Property0.000.000.00
Cash4.160.084.08
Other1.190.001.19
World Regions30/11/2019
 % of EquityRelative to Category
United States85.860.96
Canada0.000.00
Latin America0.00-
United Kingdom1.000.63
Eurozone4.411.18
Europe - ex Euro3.681.37
Europe - Emerging0.00-
Africa0.00-
Middle East0.000.00
Japan2.123.02
Australasia0.000.00
Asia - Developed0.000.00
Asia - Emerging2.932.00
 
Sector Weightings30/11/2019
 % of EquityRelative to Category
HealthcareHealthcare100.001.02
 
Top 10 Holdings30/11/2019
 Portfolio
Total Number of Equity Holdings47
Total Number of Bond Holdings0
Assets in Top 10 Holdings50.81
NameSectorCountry% of Assets
Amgen Inc206United States9.07
Biogen Inc206United States7.24
Alexion Pharmaceuticals Inc206United States6.31
Regeneron Pharmaceuticals Inc206United States5.03
Gilead Sciences Inc206United States4.82
Vertex Pharmaceuticals Inc206United States4.23
Biomarin Pharmaceutical Inc206United States4.04
Seattle Genetics Inc206United States3.69
Illumina Inc206United States3.28
Incyte Corp206United States3.09
 
 
Advertisement
In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites